Clinical Trials Logo
  1. Home
  2. Metastases
  3. NCT01442246

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Metastases Clinical Trial

Official title:
Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.

Clinical Trial Summary

PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence. SECONDARY OBJECTIVE(S): - PSA evolution - Evaluation of testosterone level - Specific survival - Overall survival - Tolerance - Quality of life (QLQ-C30 questionnaires)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01442246
Study type Interventional
Source UNICANCER
Contact
Status Active, not recruiting
Phase Phase 3
Start date July 2011
Completion date September 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT02156700 - Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors N/A
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00094653 - MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Phase 3
Completed NCT00091832 - Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer Phase 2
Completed NCT00080301 - Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase 3
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT01678664 - Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors Phase 2
Completed NCT00083720 - Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy Phase 2
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT00096967 - A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study Phase 3
Completed NCT00097487 - A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane N/A
Completed NCT00752570 - A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05195710 - Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases Phase 1
Completed NCT00106418 - A Research Study for Patients With Prostate Cancer Phase 2
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Active, not recruiting NCT02414269 - Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Phase 1/Phase 2
Terminated NCT01759238 - Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer Phase 2
Completed NCT00107861 - Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases Phase 1/Phase 2
Completed NCT00095108 - Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer Phase 1
Terminated NCT00099281 - DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer Phase 3